Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aditxt Inc (NQ: ADTX )

0.3806 -0.0194 (-4.85%)
Streaming Delayed Price Updated: 2:30 PM EDT, Sep 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 984,299
Open 0.4000
Bid (Size) 0.3806 (85)
Ask (Size) 0.3850 (88)
Prev. Close 0.4000
Today's Range 0.3700 - 0.4000
52wk Range 0.3902 - 24.00
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
InvestorNewsBreaks – Aditxt (NASDAQ: ADTX) Subsidiary Signs Agreement with Evofem Biosciences Inc. (OTCQB: EVFM) Involving Unique Endometriosis Diagnostic Test
Via Investor Brand Network
Aditxt’s Subsidiary Pearsanta to Collaborate with Evofem Biosciences for Targeted U.S. Launch of Endometriosis Diagnostic in Mid-2025
From Aditxt, Inc.
Via Business Wire

Performance

YTD
-92.07%
-92.07%
1 Month
-59.94%
-59.94%
3 Month
-74.28%
-74.28%
6 Month
-87.68%
-87.68%
1 Year
-97.88%
-97.88%

More News

Read More
BioMedNewsBreaks — Aditxt Inc. (NASDAQ: ADTX) Enters into Second Amendment to Amended and Restated Merger Agreement with Evofem
Via Investor Brand Network
Aditxt and Evofem Sign Second Amendment to Amended and Restated Merger Agreement, Target Closing of Acquisition in Fourth Quarter of 2024
From Aditxt, Inc.
Via Business Wire
ADTX Stock Earnings: Aditxt Reported Results for Q2 2024
Via InvestorPlace
Looking Into Aditxt's Recent Short Interest
Via Benzinga
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Subsidiary Seeks Grant Funding to Advance Early Detection, Management of Prostate Cancer
Via Investor Brand Network
Aditxt Subsidiary Pearsanta Submits a Grant Application Seeking to Advance Clinical Trials for Mitomic® Prostate Test, Targeting Early Detection in High-Risk Patients
From Aditxt, Inc.
Via Business Wire
InvestorNewsBreaks – Aditxt (NASDAQ: ADTX) Announces Participation at H.C. Wainwright 26th Annual Global Investment Conference
Via Investor Brand Network
Aditxt to Present at the H.C. Wainwright 26th Annual Global Investment Conference September 9th-11th, 2024
From Aditxt, Inc.
Via Business Wire
Biotech News: Why Is Aditxt (ADTX) Stock Up 49% Today?
Via InvestorPlace
BioMedNewsBreaks — Evofem Biosciences Inc. (EVFM) Subsidiary Appoints Industry Veteran as Subsidiary President
Via Investor Brand Network
Aditxt’s Precision Health Subsidiary, Pearsanta, Appoints Christopher Mitton as President as it Seeks to Complete Clinical Validation Studies for its Mitomic® Endometriosis Test (MET™) and Mitomic® Prostate Test (MPT™)
From Aditxt, Inc.
Via Business Wire
TinyGemsBreaks – Aditxt Inc. (NASDAQ: ADTX), Appili Therapeutics (TSX: APLI) (OTC: APLIF) Enter Third Amending Agreement
Via Investor Brand Network
Aditxt Announces Third Amendment to Arrangement Agreement with Appili Therapeutics
From Aditxt, Inc.
Via Business Wire
BioMedNewsBreaks — Evofem Biosciences Inc. (EVFM) Releases Second-Quarter 2024 Financial Results, Company Update
Via Investor Brand Network
BioMedNewsBreaks — Aditxt Inc. (NASDAQ: ADTX) Releases Report on Annual Shareholders’ Meeting Activity
Via Investor Brand Network
Aditxt Announces the Successful Passage of all Proposals at Recent Annual Shareholders’ Meeting, Setting the Stage for 2024 and 2025 Strategic Plans
From Aditxt, Inc.
Via Business Wire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Via InvestorPlace
Aditxt Announces Closing of $1.2 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
From Aditxt, Inc.
Via Business Wire
TechMediaBreaks – Aditxt Inc. (NASDAQ: ADTX) Enters into $1.2M Registered Direct Offering Agreement
Via Investor Brand Network
Aditxt Announces $1.2 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
From Aditxt, Inc.
Via Business Wire
TinyGemsBreaks – Aditxt Inc. (NASDAQ: ADTX) Subsidiary Submits Proposal to CDMRP for Ovarian Cancer Detection Research Award
Via Investor Brand Network
Nasdaq Jumps 250 Points; Disney Earnings Beat Estimates
Via Benzinga
Topics Earnings
Exposures Financial
Aditxt Subsidiary Pearsanta Seeks Clinical Trial Translational Endpoints Research Award for Early Detection of Ovarian Cancer
From Aditxt, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.